279 related articles for article (PubMed ID: 26873871)
41. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
42. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
43. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.
Wu JD; Xu XH; Zhu J; Ding B; Du TX; Gao G; Mao XM; Ye L; Lee KO; Ma JH
Diabetes Technol Ther; 2011 Feb; 13(2):143-8. PubMed ID: 21284481
[TBL] [Abstract][Full Text] [Related]
44. [Improved blood sugar control plus weight loss].
Göke B
MMW Fortschr Med; 2006 Aug; 148(33-34):51. PubMed ID: 16981389
[No Abstract] [Full Text] [Related]
45. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
[TBL] [Abstract][Full Text] [Related]
46. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
[TBL] [Abstract][Full Text] [Related]
47. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
48. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
49. [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Kress S
Dtsch Med Wochenschr; 2010 May; 135(18):907-10. PubMed ID: 20425675
[TBL] [Abstract][Full Text] [Related]
50. Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
Topyildiz F; Kiyici S; Gul Z; Sigirli D; Guclu M; Kisakol G; Cavun S
J Diabetes Res; 2016; 2016():1309502. PubMed ID: 26998491
[TBL] [Abstract][Full Text] [Related]
51. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
[TBL] [Abstract][Full Text] [Related]
52. Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
Nagakura J; Yamakawa T; Taguri M; Tsuchiya H; Shigematsu E; Suzuki J; Morita S; Kadonosono K; Terauchi Y
Endocr J; 2016; 63(3):239-47. PubMed ID: 26743240
[TBL] [Abstract][Full Text] [Related]
53. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
[TBL] [Abstract][Full Text] [Related]
54. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Lee WC; Conner C; Hammer M
Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
[TBL] [Abstract][Full Text] [Related]
55. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
56. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
57. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
[TBL] [Abstract][Full Text] [Related]
58. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ; Moniri NH; Smiley DD
Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
[TBL] [Abstract][Full Text] [Related]
59. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
